doi: 10.12938/bmfh.2022-005 19
Lawsuits filed against Ozempics manufacturer, Novo Nordisk, allege that the company did not properly warn patients or doctors about some of the serious side effects of the drug, leading to serious injuries for some people
As such, this medication delivers dual advantages by aiding glycemic control while concurrently lessening potential complications linked with diabetes
The table shows that resmetirom is a small (molecular weight about 600 g/mol), non-iodinated THR- agonist administered once daily as an oral tablet, while semaglutide is a large (about 4 kDa) GLP-1 peptide designed for once-weekly subcutaneous injection or, with SNAC enhancement, once-daily oral administration
This efficacy suggests the drug could be suitable for patients with greater weight loss needs, including as an alternative to more invasive treatments like bariatric surgery
Type III and IV individuals demonstrate visible darkening within 1421 days but continue deepening through week 8